MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding MoonLake Immunotherapeutics changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 46 | 43 | −3 |
| Shares | 11.2M | 11.2M | +24.5K (+0.2%) |
| Value | $115.8M | $111.1M | −$4.70M (−4.1%) |
New holders (1)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cowen and Company, LLC | 62,475 | $622.0K | 0.03% |
Sold out (4)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Logos Global Management LP | 50,000 | $518.0K |
| Maven Securities LTD | 50,000 | $513.0K |
| Panagora Asset Management Inc | 7,212 | $74.0K |
| UBS Group AG | 374 | $4.00K |